Rituximab, methotrexate, carmustine, etoposide, and prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: A retrospective single-center study Journal Article

   

Authors:	Reiss, S. N.; Yerram, P.; Modelevsky, L.; Grommes, C.
Article Title:	Rituximab, methotrexate, carmustine, etoposide, and prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: A retrospective single-center study
Abstract:	Relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) has a poor prognosis with no established preferred treatment. We report the efficacy and toxicity of a combination chemotherapy regimen: methotrexate, carmustine, etoposide, and prednisone with or without rituximab (RMBVP). This retrospective study included thirty patients who received a median of two 28-day cycles (0.5–5). The median age was 66 years (23–81); median KPS was 70 (30–90); 14 (46.7%) were women. Patients received a median of 2 prior lines of therapy and all received prior methotrexate. Of 29 evaluable patients, the overall response rate was 73.3% (n = 22). Median progression-free survival (PFS) was 15.6 months. Patients who recurred or progressed <12 months since last chemotherapy had a shorter median PFS (7.6 vs 37.6 months). Toxicity was moderate with 20% rates of severe myelosuppression. RMBVP is a tolerable treatment option for R/R PCNSL, with favorable response rates in those with recurrent disease. © 2021 Informa UK Limited, trading as Taylor & Francis Group.
Keywords:	adult; clinical article; aged; overall survival; lenalidomide; prednisone; neutropenia; cancer recurrence; salvage therapy; drug efficacy; primary central nervous system lymphoma; cytarabine; methotrexate; rituximab; drug megadose; follow up; progression free survival; multiple cycle treatment; nephrotoxicity; anemia; bone marrow suppression; etoposide; leukopenia; thrombocytopenia; retrospective study; carmustine; folinic acid; recurrent disease; antiemetic agent; hyperbilirubinemia; observational study; granulocyte colony stimulating factor; disease exacerbation; hydration; hypertransaminasemia; overall response rate; lymphoma and hodgkin disease; chemotherapeutic approaches; ibrutinib; pharmacotherapeutics; human; male; female; article; patient history of chemotherapy; rehydration
Journal Title:	Leukemia and Lymphoma
Volume:	63
Issue:	3
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2022-01-01
Start Page:	627
End Page:	632
Language:	English
DOI:	10.1080/10428194.2021.1998481
PUBMED:	34758711
PROVIDER:	scopus
PMCID:	PMC9703641
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119209209&doi=10.1080%2f10428194.2021.1998481&partnerID=40&md5=323cbd75bb9a12bd015010bcdd185d9f
Notes:	Article -- Export Date: 1 April 2022 -- Funding details: National Institutes of Health, NIH -- Funding details: National Cancer Institute, NCI, P30 CA008748 -- Funding details: Leukemia and Lymphoma Society, LLS -- Funding text 1: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. CG was supported by grants from Cycle for Survival Equinox and the Leukemia & Lymphoma Society. -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/197360